Qu Biologics is a private clinical-stage biopharmaceutical company incorporated in the province of British Columbia, Canada, in Sept. 2007. Qu Biologics has raised $9.2M to date from angel investors and an additional $2.9M in government funding, through the National Research Council Industrial Research Assistance Program (NRC-IRAP), the Scientific Research and Experimental Development (SR&ED) Tax Incentive Program and the US National Cancer Institute (NCI).
Qu Biologics is currently seeking to raise additional funds to expand their clinical trial program to include additional indications in cancer (e.g., late-stage lung cancer, late-stage colon cancer, inoperable pancreatic cancer) and immune-related disease (e.g., rheumatoid arthritis and ulcerative colitis). In addition, Qu is looking for investment to finance the large-scale good manufacturing practices (GMP)-accredited manufacture of their lead candidate Site Specific Immunomodulator (SSI) in preparation for a phase 3 multi-national clinical trial in Crohn’s disease.
» If you are interested in learning more about investment opportunities with Qu Biologics, please enter your contact information here.